Tarsus Pharmaceuticals, Inc.
TARS
Rang in aandelen
#4544
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aandeelprijs
$70.61
Marktkapitalisatie
$3.30B
Verandering (1 dag)
0.16%
Verandering (1 jaar)
2.78%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Categorie
Healthcare
Koersgeschiedenis voor Tarsus Pharmaceuticals, Inc. (TARS)
Hoogste slotkoers: $72.14 op 2026-10-01
Laagste slotkoers: $21.51 op 2020-10-01
Laagste slotkoers: $21.51 op 2020-10-01
Koersgeschiedenis van Tarsus Pharmaceuticals, Inc. van 2020 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $534.12 | 25.25% |
US
|
|
| $231.12 | 760.78% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $880.75 | 8.18% |
NL
|
|
| $289.51 | 1.72% |
BE
|
